Olaparib in the management of ovarian cancer

Alterations in the homologous repair pathway are thought to occur in 30%–50% of epithelial ovarian cancers. Cells deficient in homologous recombination rely on alternative pathways for DNA repair in order to survive, thereby providing a potential target for therapy. Olaparib, a poly(ADP-ribose) poly...

Descripción completa

Detalles Bibliográficos
Autores principales: Bixel, Kristin, Hays, John L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538690/
https://www.ncbi.nlm.nih.gov/pubmed/26309417
http://dx.doi.org/10.2147/PGPM.S62809
_version_ 1782386016186793984
author Bixel, Kristin
Hays, John L
author_facet Bixel, Kristin
Hays, John L
author_sort Bixel, Kristin
collection PubMed
description Alterations in the homologous repair pathway are thought to occur in 30%–50% of epithelial ovarian cancers. Cells deficient in homologous recombination rely on alternative pathways for DNA repair in order to survive, thereby providing a potential target for therapy. Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian cancer. This review article will provide an overview of the BRCA genes and homologous recombination, the role of PARP in DNA repair and the biological rationale for the use of PARP inhibitors as cancer therapy, and ultimately will focus on the use of olaparib in the management of ovarian cancer.
format Online
Article
Text
id pubmed-4538690
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45386902015-08-25 Olaparib in the management of ovarian cancer Bixel, Kristin Hays, John L Pharmgenomics Pers Med Review Alterations in the homologous repair pathway are thought to occur in 30%–50% of epithelial ovarian cancers. Cells deficient in homologous recombination rely on alternative pathways for DNA repair in order to survive, thereby providing a potential target for therapy. Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian cancer. This review article will provide an overview of the BRCA genes and homologous recombination, the role of PARP in DNA repair and the biological rationale for the use of PARP inhibitors as cancer therapy, and ultimately will focus on the use of olaparib in the management of ovarian cancer. Dove Medical Press 2015-08-07 /pmc/articles/PMC4538690/ /pubmed/26309417 http://dx.doi.org/10.2147/PGPM.S62809 Text en © 2015 Bixel and Hays. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Bixel, Kristin
Hays, John L
Olaparib in the management of ovarian cancer
title Olaparib in the management of ovarian cancer
title_full Olaparib in the management of ovarian cancer
title_fullStr Olaparib in the management of ovarian cancer
title_full_unstemmed Olaparib in the management of ovarian cancer
title_short Olaparib in the management of ovarian cancer
title_sort olaparib in the management of ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538690/
https://www.ncbi.nlm.nih.gov/pubmed/26309417
http://dx.doi.org/10.2147/PGPM.S62809
work_keys_str_mv AT bixelkristin olaparibinthemanagementofovariancancer
AT haysjohnl olaparibinthemanagementofovariancancer

Ejemplares similares